Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results
Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met its safety and efficacy endpoints also for these dose ranges, and thus for the study in its entirety.COUGH-1 headline results Positive initial data from the first-in-human study of ABNCoV2, the capsid virus like particle (